Strides Pharma's Major Win: USFDA Approval for Sucralfate Generic

Strides Pharma Science's unit, Strides Pharma Global Pte. Ltd, has secured USFDA approval for a generic version of Sucralfate Oral Suspension (1gm/10mL), a treatment for gastrointestinal diseases. This bioequivalent product taps into a $124 million market in the US, boosting the company's shares by 6.33% to Rs 899.75 on the BSE.

Strides Pharma Science on Wednesday said its unit has received approval from the US health regulator to market a generic medication used in the treatment of gastrointestinal diseases.

Singapore-based Strides Pharma Global Pte. Ltd, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the US Food & Drug Administration (USFDA), the drug firm said in a statement.

The product is bioequivalent and therapeutically equivalent to AbbVie's Carafate (1gm/10mL).

Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.

As per IQVIA, Sucralfate Oral Suspension (1gm/10 mL) had a market size of USD 124 million in the US market.

Shares of the company were trading 6.33 per cent up at Rs 899.75 apiece on the BSE.